Updates

Sanderson

September 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Sanderson’s H1 showed positive developments in several key areas. Sales were £48.3m, down 3%. Within that, Brand revenue fell 5% to £34.7m, with North America - the strategic focus - up 4% to £11.2m, while the UK and Europe declined 9% and 10%, respectively. The Morris & Co DTC site, launched in the US in March, is performing ahead of expectations and DTC platforms for Sanderson and Harlequin will follow shortly. Manufacturing is on course to now be better than breakeven this year (Anstey is profitable), versus a £2.6m loss last year. Licensing increased 6% to £4.4m (from £4.1m) with 22% growth in underlying performance excluding accelerated income under IFRS 15. Helped by stronger brand product revenue in the final nin ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Tristel

Anpario

Sanderson - H2 sales start positively in the UK and US (November 2025)

Sanderson - Sharp recovery seen in May and June (August 2025)

Sanderson (February 2025)

Sanderson (September 2024)

Sanderson - Ex-cash PE of 6.1 (April 2024)

Sanderson (August 2023)

Sanderson (April 2023)

Sanderson Design - Ex cash PE of 7 (November 2022)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X